The United Kingdom and the United States have secured a major trade agreement that will keep no tariffs on British pharmaceutical products going into the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to raise funding on medicines through the NHS. This pledge secures that duties on these vital products will stay at zero for a period of three years.
This agreement comes after previous statements to dramatically increase tariffs on branded pharmaceutical imports, with increases floated up to 100%.
"This arrangement between the UK strengthens the global environment for new treatments and introduces much-needed fairness to American-British pharmaceutical trade," a statement noted.
Trade Significance
Drugs constitute one of the UK's biggest goods shipped to the United States, which is easily the largest destination for leading companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months leading up to September, the UK exported medicines worth billions to the US. This value made up a significant portion of all goods exports in that timeframe.
"This guarantee secures employment, boosts investment and facilitates the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary stated.
Specific British Pledges
The agreement involves several notable changes from the UK:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to double total public funding on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The percentage drug companies must return to the NHS to stay within budget will be restricted at 15%. Previously, repayments exceeded twenty percent.
Broader Context
The deal comes amid a long-running dispute between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
This friction were heightened by arguments that American consumers were paying several times more for the identical medicines than people in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been halted or cancelled, while substantial funding commitments have been announced toward American operations.
A senior figure acknowledged that the NHS must spend more on medicines, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the last ten years.
